Drug Profile
Research programme: epidermyolysis bullosa dystrophica therapies - Immusoft
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Immusoft
- Class Cell therapies; Gene therapies; Skin disorder therapies
- Mechanism of Action Collagen stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epidermolysis bullosa dystrophica
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Epidermolysis bullosa dystrophica in USA (IV) prior to September 2023 (Immusoft pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Epidermolysis-bullosa dystrophica in USA (IV)
- 05 Jan 2018 Preclinical development is underway in USA (Immusoft pipeline, January 2018)